| Property | Value |
|---|
|
?:abstract
|
-
In the context of the SARS-CoV-2 pandemic, hydroxychloroquine has been proposed as a potential agent to treat COVID-19 patients. Older adults are more susceptible to COVID-19 and some patients may require admission in intensive care units, where oral drug administration of solid forms may be compromised in many COVID-19 patients. However, liquid formulation of hydroxychloroquine is not commercially available. This study describes how to prepare a 50 mg/mL hydroxychloroquine oral suspension using hydroxychloroquine sulfate powder and Syrspend SF dry pH4® suspending vehicle. Moreover, a fully validated stability indicating method has been developed to demonstrate the physicochemical stability of the compounded hydroxychloroquine oral suspension over 60 days under refrigeration (5 ± 3°C). Finally, use of the proposed oral suspension provides a reliable solution to perform safe and accurate administration of hydroxychloroquine to patients with SARS-CoV-2 infection.
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
-
10.1016/j.ijantimicag.2020.106201
|
|
?:journal
|
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/81a327a97327317035edd30bc1a88dd00b9ec353.json
|
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7566679.xml.json
|
|
?:pmcid
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
Preparation and physicochemical stability of 50 mg/ml hydroxychloroquine oral suspension in Syrspend pH4 dry
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}